<DOC>
	<DOCNO>NCT01925209</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerability multiple dos bimagrumab/BYM338 vs placebo , administer intravenously ( i.v . ) , physical function , muscle strength , mobility patient sporadic inclusion body myositis ( sIBM )</brief_summary>
	<brief_title>Efficacy Safety Bimagrumab/BYM338 52 Weeks Physical Function , Muscle Strength , Mobility sIBM Patients</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>Diagnosed sporadic inclusion body myositis ; Must able walk ( assistive aid allow , include intermittent use wheelchair ) ; Must condition significantly limit ability move around ; Must use corticosteroid . Must use systemic corticosteroid ( daily dose &gt; =10mg prednisone ) past 3 month ; Must meet cardiovascular requirement ; Must pregnant nursing ; Must chronic active infection ( e.g. , HIV , hepatitis B C , tuberculosis , etc ) ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sporadic inclusion body myositis ,</keyword>
	<keyword>myositis ,</keyword>
	<keyword>muscle wasting ,</keyword>
	<keyword>control clinical trial ,</keyword>
	<keyword>randomize ,</keyword>
	<keyword>body mass ,</keyword>
	<keyword>muscle function ,</keyword>
	<keyword>strength ,</keyword>
	<keyword>performance ,</keyword>
	<keyword>physical function</keyword>
</DOC>